Answers are grounded in this paper and cite their sources.
Background Myotonic dystrophy type 1 is an autosomal dominant disorder that leads to progressive weakness, myotonia, and multisystemic disease burden. The primary pathogenic event, a toxic CUG repeat expansion, is potentially treatable with precision genetic therapeutics. As a result, multiple potential disease modifying therapies have advanced to clinical trials. However, standalone single therapy trials may compete for participants and sites, slowing advancement. Here we explore a potential platform trial design. Methods The overall platform designs selected were based on similar designs in other neurodegenerative disorders. The authors utilized a large natural history dataset, END-DM1, to explore potential primary endpoints. Using the 10-meter walk/run time as an example, the authors compared an idealized no-competition standalone benchmark; 3, 5, and 8 concurrently recruiting standalone trials; and a platform trial with three concurrent regimens and shared concurrent controls. The primary comparison is between the platform and competing trials. The primary simulations assumed that 10% of trials/regimens were effective with an effect of 0.6 standard deviations, while the ineffective 90% of trials/regimens had no effect. Competing approaches compared multiple metrics, including time to the first positive result, participant use, regimen-level type-I error and power, and program-level false-positive rates. Results The fully utilized three-regimen platform with N = 80 per regimen and shared controls preserved power compared to standalone trials and reduced the overall duration and participant usage of the clinical trial. With an annual pool of 150 participants, the mean time to first positive result was 6.1 years for the fully utilized platform, compared with 8.8 and 9.7 years for the three and five competing standalone trials. Mean enrollment was 921.7 participants for the fully utilized platform and 1,320.2 and 1,458.2 participants for the three and five competing standalone trials. Conclusions Platform clinical trial designs may increase the efficiencies of therapeutic trials, particularly when there are multiple competing therapeutic trials. In myotonic dystrophy type 1, where multiple therapeutics have the potential to address the genetic defect, platform trials may promote the rapid access of therapies to clinicians and patients.
No takes yet. Share an insight, caveat, or question.
White et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: